PerspectiveCancer and Metabolism

Metabolic Syndromes and Malignant Transformation: Where the Twain Shall Meet

See allHide authors and affiliations

Science Translational Medicine  20 Oct 2010:
Vol. 2, Issue 54, pp. 54ps50
DOI: 10.1126/scitranslmed.3001669

You are currently viewing the abstract.

View Full Text


Recurrent somatic mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes that result in the accumulation of D-2-hydroxyglutarate (D-2-HG) have been identified in malignant gliomas and in acute myeloid leukemia (AML). However, the function of this metabolite in normal and malignant tissues remains uncertain. A report in the current issue of Science describes a germline IDH2 mutation in a subset of patients with a rare metabolic disorder—D-2-hydroxyglutaric aciduria—that is similar to mutations seen in cancer patients. These observations further elucidate the effects of IDH mutations on normal and malignant cells.


  • Citation: N. Bhagwat, R. L. Levine, Metabolic syndromes and malignant transformation: Where the twain shall meet. Sci. Transl. Med. 2, 54ps50 (2010).

View Full Text